FY2025 EPS Estimates for Haemonetics Cut by Zacks Research

Haemonetics Co. (NYSE:HAE) – Equities research analysts at Zacks Research reduced their FY2025 earnings estimates for Haemonetics in a research note issued to investors on Monday, February 17th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $4.56 per share for the year, down from their prior forecast of $4.58. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.23 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.24 EPS, Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $5.06 EPS, Q1 2027 earnings at $1.39 EPS, Q2 2027 earnings at $1.47 EPS and FY2027 earnings at $5.83 EPS.

A number of other research firms have also recently weighed in on HAE. Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $95.00 to $68.00 in a report on Friday, February 7th. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a research report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective for the company. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC lowered their target price on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Barrington Research decreased their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Price Performance

Shares of NYSE HAE opened at $64.14 on Wednesday. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The company’s 50-day moving average price is $73.77 and its 200 day moving average price is $77.03. Haemonetics has a 52 week low of $58.80 and a 52 week high of $97.97. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of 25.25, a PEG ratio of 1.09 and a beta of 0.39.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

Hedge Funds Weigh In On Haemonetics

A number of large investors have recently modified their holdings of HAE. TD Waterhouse Canada Inc. purchased a new position in Haemonetics in the fourth quarter valued at approximately $25,000. Covestor Ltd raised its stake in shares of Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after acquiring an additional 439 shares during the period. Whittier Trust Co. acquired a new position in shares of Haemonetics during the 4th quarter valued at $62,000. Nisa Investment Advisors LLC boosted its position in Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares during the period. Finally, Parkside Financial Bank & Trust boosted its position in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.